Azapiron

Iz Wikipedije, slobodne enciklopedije
Buspiron, prototipski azapironski angziolitik, koji sadrži azaspirodekandion i pirimidinilpiperazin vezan preko butil lanca.

Azapironi su klasa lekova koji se koriste kao anksiolitici i antipsihotici.[1][2][3][4] Oni se isto tako koriste kao zamena za antidepresive poput selektivnih inhibitora preuzimanja serotonina (SSRI).[5][6][7][8][9]

Reference[uredi - уреди | uredi izvor]

  1. Eison AS (June 1990). "Azapirones: history of development". Journal of Clinical Psychopharmacology 10 (3 Suppl): 2S–5S. PMID 1973936. 
  2. Cadieux RJ (May 1996). "Azapirones: an alternative to benzodiazepines for anxiety". American Family Physician 53 (7): 2349–53. PMID 8638511. 
  3. Chessick CA, Allen MH, Thase M et al. (2006). Chessick, Cheryl A, ed. "Azapirones for generalized anxiety disorder". Cochrane Database of Systematic Reviews (Online) 3: CD006115. PMID 16856115. doi:10.1002/14651858.CD006115. 
  4. Feighner JP, Boyer WF (1989). "Serotonin-1A anxiolytics: an overview". Psychopathology. 22 Suppl 1: 21–6. PMID 2567039. 
  5. Van Ameringen M, Mancini C, Wilson C (July 1996). "Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia". Journal of Affective Disorders 39 (2): 115–21. PMID 8827420. doi:10.1016/0165-0327(96)00030-4. 
  6. Bouwer C, Stein DJ (April 1997). "Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression". South African Medical Journal 87 (4 Suppl): 534–7, 540. PMID 9180827. 
  7. Dimitriou EC, Dimitriou CE (December 1998). "Buspirone augmentation of antidepressant therapy". Journal of Clinical Psychopharmacology 18 (6): 465–9. PMID 9864079. doi:10.1097/00004714-199812000-00009. 
  8. Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH (June 2001). "Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study". The Journal of Clinical Psychiatry 62 (6): 448–52. PMID 11465522. doi:10.4088/JCP.v62n0608. 
  9. Yamada K, Yagi G, Kanba S (April 2003). "Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial". Psychiatry and Clinical Neurosciences 57 (2): 183–7. PMID 12667165. doi:10.1046/j.1440-1819.2003.01099.x.